ReviewClinical and experimental gastroenterology2025
Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease.
Review in Clinical and experimental gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the success of monoclonal antibody (mAb) therapies in treating inflammatory bowel disease (IBD), a persistent therapeutic ceiling remains. This comprehensive review explores emerging strategies to enhance the efficacy of mAb-based treatments. Key among these is the development of bispecific antibodies designed to simultaneously engage two cytokine targets, offering dual blockade of inflammatory pathways and the potential for synergistic effects. Co-formulation approaches, comprising two or more mAbs within a single therapeutic product, are also examined as a means of broadening immunologic coverage and streamlining delivery. Finally, advances in pharmacokinetic optimisation are discussed, including Fc region modifications, polyethylene glycol conjugation, albumin fusion, and glycoengineering, all aimed at reducing immunogenicity and extending half-life. Together, these strategies represent a path toward next-generation biologics with the potential to minimise current limitations in IBD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.